The Latest Psychedelics Articles from Streetwise Reports


Pharma Company Working to Unlock Psychedelic Drug's Potential for Stroke Recovery

  ()
Algernon Pharmaceuticals CEO Christopher J. Moreau and Dr. David Nutt, the company's research stroke consultant, discuss Algernon's upcoming Phase 1 study of DMT for stroke. read more >

Promising Psychedelic Drug Trials Show Potential for a New Biotech Boom

Contributed Research
  ()
McAlinden Research Partners notes that continued advances in psychedelic therapies show potential to drive an investment boom that could reshape the future of medicine and mental health therapies. read more >
News Update

Firm Doubles in Size by Adding Four New Psychedelic Mental Health Clinics

News Update
  ()
Novamind Inc. is opening four new psychedelic mental health clinics as part of the company's national expansion strategy, giving it the capability to conduct 65,000 client visits in 2021. read more >

Merck Selects Rapidly Growing Psychedelic Medicine Company as Key Research Site

  ()
Novamind runs clinics, research sites and therapeutic retreats and is positioning itself for expansion. read more >
Showing Results: 1 to 4 of 4

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"An extension of PVG's West zone returned 3,660 g/t over 1m."
– Andrew Mikitchook, BMO Capital Markets
"GCX reported an impressive hit from a hole drilled on Carmacks."
– Brien Lundin, Gold Newsletter (Jefferson Financial)
"Drilling makes CBR a compelling lever in a looming fall gold price boom."
– Brien Lundin, Gold Newsletter (Jefferson Financial)